Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Germing

Showing results (291-300 of 339) with videos related to

Pageof 34
Sort By:
Blood Advances|July 25, 2018
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Theo de Witte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2022
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO NetworkRaphael Itzykson, Valeria Santini, Sylvain Thepot, et al.
Haematologica|October 15, 2020
Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspectiveTheo De Witte, Luca Malcovati, Pierre Fenaux, et al.
The Lancet. Haematology|February 7, 2017
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trialEsther N Oliva, Caterina Alati, Valeria Santini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative GroupStefan Gröschel, Richard F Schlenk, Jan Engelmann, et al.
Haematologica|July 7, 2019
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registryMarlijn Hoeks, Ge Yu, Saskia Langemeijer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2019
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II TrialMichael Lübbert, Olga Grishina, Claudia Schmoor, et al.
Blood|January 6, 2026
Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemiaHartmut Döhner, Daniela Späth, Maral Saadati, et al.
Haematologica|April 26, 2012
Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosisJulien Broseus, Lourdes Florensa, Esther Zipperer, et al.
Blood Advances|August 26, 2020
Guideline-based indicators for adult patients with myelodysplastic syndromesKristina Stojkov, Tobias Silzle, Georg Stussi, et al.
Pageof 34

Showing results (291-300 of 339) with videos related to

Sort By:
Pageof 34
Blood Advances|July 25, 2018
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Theo de Witte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2022
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO NetworkRaphael Itzykson, Valeria Santini, Sylvain Thepot, et al.
Haematologica|October 15, 2020
Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspectiveTheo De Witte, Luca Malcovati, Pierre Fenaux, et al.
The Lancet. Haematology|February 7, 2017
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trialEsther N Oliva, Caterina Alati, Valeria Santini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative GroupStefan Gröschel, Richard F Schlenk, Jan Engelmann, et al.
Haematologica|July 7, 2019
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registryMarlijn Hoeks, Ge Yu, Saskia Langemeijer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2019
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II TrialMichael Lübbert, Olga Grishina, Claudia Schmoor, et al.
Blood|January 6, 2026
Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemiaHartmut Döhner, Daniela Späth, Maral Saadati, et al.
Haematologica|April 26, 2012
Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosisJulien Broseus, Lourdes Florensa, Esther Zipperer, et al.
Blood Advances|August 26, 2020
Guideline-based indicators for adult patients with myelodysplastic syndromesKristina Stojkov, Tobias Silzle, Georg Stussi, et al.
Pageof 34